Media headlines about Axovant Sciences (NASDAQ:AXON) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axovant Sciences earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.2563605603023 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

AXON has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Axovant Sciences in a research note on Thursday, October 19th. Chardan Capital reaffirmed a “sell” rating and set a $3.00 price objective on shares of Axovant Sciences in a research note on Friday, November 3rd. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Robert W. Baird reaffirmed a “hold” rating and set a $6.00 price objective on shares of Axovant Sciences in a research note on Wednesday, November 1st. Finally, Cowen downgraded shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research note on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $13.61.

Shares of Axovant Sciences (NASDAQ AXON) traded down $0.03 during trading hours on Friday, hitting $1.91. The stock had a trading volume of 1,220,000 shares, compared to its average volume of 2,090,000. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34. Axovant Sciences has a 1-year low of $1.77 and a 1-year high of $27.98. The stock has a market cap of $205.73 and a PE ratio of -0.83.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/12/axovant-sciences-axon-receiving-somewhat-favorable-media-coverage-study-shows.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Insider Buying and Selling by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.